Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal von Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

Volltext

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan von Okusaka, T, Nakachi, K, Fukutomi, A, Mizuno, N, Ohkawa, S, Funakoshi, A, Nagino, M, Kondo, S, Nagaoka, S, Funai, J, Koshiji, M, Nambu, Y, Furuse, J, Miyazaki, M, Nimura, Y

Volltext

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 von Ott, P.A, Piha-Paul, S.A, Munster, P, Pishvaian, M.J, Van Brummelen, E, Cohen, R, Gomez-Roca, C, Ejadi, S, Stein, M, Chan, E, Simonelli, M, Morosky, A, Yuan, S.S, Koshiji, M, Bennouna, J

Volltext

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency von Le, Dung T, Uram, Jennifer N, Wang, Hao, Bartlett, Bjarne R, Kemberling, Holly, Eyring, Aleksandra D, Skora, Andrew D, Luber, Brandon S, Azad, Nilofer S, Laheru, Dan, Biedrzycki, Barbara, Donehower, Ross C, Zaheer, Atif, Fisher, George A, Crocenzi, Todd S, Lee, James J, Duffy, Steven M, Goldberg, Richard M, de la Chapelle, Albert, Koshiji, Minori, Bhaijee, Feriyl, Huebner, Thomas, Hruban, Ralph H, Wood, Laura D, Cuka, Nathan, Pardoll, Drew M, Papadopoulos, Nickolas, Kinzler, Kenneth W, Zhou, Shibin, Cornish, Toby C, Taube, Janis M, Anders, Robert A, Eshleman, James R, Vogelstein, Bert, Diaz, Luis A

Volltext

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 von Bang, Y.J, Doi, T, Braud, F. De, Piha-Paul, S, Hollebecque, A, Razak, A.R. Abdul, Lin, C.C, Ott, P.A, He, A.R, Yuan, S.S, Koshiji, M, Lam, B, Aggarwal, R

Volltext

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 von O'Neil, B.H, Wallmark, J, Lorente, D, Elez, E, Raimbourg, J, Gomez-Roca, C, Ejadi, S, Piha-Paul, S.A, Moss, R.A, Siu, L.L, Dotti, K, Santoro, A, Gould, M, Yuan, S.S, Koshiji, M, Han, S.W

Volltext

Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor‐alpha (TNF‐α) and/or interferon‐gamma (IFN‐γ), resulting from down‐modulation of Bcl‐2 expression... von KOSHIJI, M, ADACHI, Y, SOGO, S, TAKETANI, S, OYAIZU, N, THAN, S, INABA, M, PHAWA, S, HIOKI, K, IKEHARA, S

Volltext

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gas... von Catenacci, D., Rosales, M. Koshiji, Chung, H., Yoon, H., Shen, L., Moehler, M., Kang, Y.

Volltext

HIF-1α induces cell cycle arrest by functionally counteracting Myc von Koshiji, Minori, Kageyama, Yukio, Pete, Erin A, Horikawa, Izumi, Barrett, J Carl, Huang, L Eric

Volltext

HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression von Koshiji, Minori, To, Kenneth K.-W., Hammer, Stefanie, Kumamoto, Kensuke, Harris, Adrian L., Modrich, Paul, Huang, L. Eric

Volltext

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial von Muro, Kei, Dr, Chung, Hyun Cheol, Prof, Shankaran, Veena, MD, Geva, Ravit, MD, Catenacci, Daniel, MD, Gupta, Shilpa, MD, Eder, Joseph Paul, MD, Golan, Talia, MD, Le, Dung T, MD, Burtness, Barbara, MD, McRee, Autumn J, MD, Lin, Chia-Chi, MD, Pathiraja, Kumudu, MA, Lunceford, Jared, PhD, Emancipator, Kenneth, MD, Juco, Jonathan, MD, Koshiji, Minori, MD, Bang, Yung-Jue, Prof

Volltext

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junc... von Catenacci, D., Koshiji Rosales, M., Chung, H., Yoon, H., Moehler, M., Kang, Y., Shen, L.

Volltext

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlle... von Fuchs, Charles S, Dr Prof, Tomasek, Jiri, MD, Yong, Cho Jae, Prof, Dumitru, Filip, MD, Passalacqua, Rodolfo, MD, Goswami, Chanchal, Prof, Safran, Howard, Prof, dos Santos, Lucas Vieira, MD, Aprile, Giuseppe, MD, Ferry, David R, Prof, Melichar, Bohuslav, Prof, Tehfe, Mustapha, MD, Topuzov, Eldar, Prof, Zalcberg, John Raymond, Prof, Chau, Ian, MD, Campbell, William, Prof, Sivanandan, Choondal, MD, Pikiel, Joanna, MD, Koshiji, Minori, MD, Hsu, Yanzhi, PhD, Liepa, Astra M, PharmD, Gao, Ling, PhD, Schwartz, Jonathan D, MD, Tabernero, Josep, MD

Volltext

232TiP KEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma von Ohtsu, A., Tabernero, J., Bang, Y.-J., Fuchs, C.S., Sun, L., Wang, Z., Csiki, I., Koshiji, M., Van Cutsem, E.

Volltext

231TiP KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma von Van Cutsem, E., Fuchs, C.S., Denker, A.E., Tabernero, J., Ohtsu, A., Lam, B., Koshiji, M., Bang, Y.-J.

Volltext

KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer von Wainberg, Z.A., Jalal, S., Muro, K., Yoon, H.H., Garrido, M., Golan, T., Doi, T., Catenacci, D.V., Geva, R., Ku, G., Bleeker, J., Bang, Y-J., Hara, H., Chung, H.C., Savage, M., Wang, J., Koshiji, M., Dalal, R., Fuchs, C.S.

Volltext

P-105 Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study von Fuchs, C., Denker, A., Tabernero, J., Van Cutsem, E., Ohtsu, A., Lam, B., Koshiji, M., Bang, Y.-J.

Volltext

P-106 Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNO... von Ohtsu, A., Tabernero, J., Bang, Y.-J., Fuchs, C., Sun, L., Wang, Z., Csiki, I., Koshiji, M., Van Cutsem, E.

Volltext

Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells von Fukuda, Kazunori, Hibiya, Yuko, Mutoh, Michihiro, Koshiji, Masatoshi, Akao, Seigou, Fujiwara, Hisayoshi

Volltext

Tumor suppressor p53 represses transcription of RECQ4 helicase von Sengupta, Sagar, Shimamoto, Akira, Koshiji, Minori, Pedeux, Remy, Rusin, Marek, Spillare, Elisa A, Shen, Jiang Cheng, Huang, L Eric, Lindor, Noralane M, Furuichi, Yasuhiro, Harris, Curtis C

Volltext